array(40) {
  [0]=>
  string(4) "2105"
  ["article_id"]=>
  string(4) "2105"
  [1]=>
  string(105) "New research showing consumer response to health claims 'should raise alarm bells for regulators'"
  ["article_title"]=>
  string(105) "New research showing consumer response to health claims 'should raise alarm bells for regulators'"
  [2]=>
  string(150) "Researchers have found that the type of health claim on foods can be completely uncorrelated with actual nutritional quality yet these messages direct"
  ["short_description"]=>
  string(150) "Researchers have found that the type of health claim on foods can be completely uncorrelated with actual nutritional quality yet these messages direct"
  [3]=>
  string(236) "Researchers have found that the type of health claim on foods can be completely uncorrelated with actual nutritional quality yet these messages directly influence consumers' expectations of healthiness and prompt their food choices."
  ["description"]=>
  string(236) "Researchers have found that the type of health claim on foods can be completely uncorrelated with actual nutritional quality yet these messages directly influence consumers' expectations of healthiness and prompt their food choices."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(199) "https://www.nutraingredients.com/Article/2019/04/30/New-research-showing-consumer-response-to-health-claims-should-raise-alarm-bells-for-regulators?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(199) "https://www.nutraingredients.com/Article/2019/04/30/New-research-showing-consumer-response-to-health-claims-should-raise-alarm-bells-for-regulators?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-04-30 19:00:00"
  ["add_date"]=>
  string(19) "2019-04-30 19:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:32"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4535"
  ["article_id"]=>
  string(4) "4535"
  [1]=>
  string(31) "Rare Disease Diagnostics Summit"
  ["article_title"]=>
  string(31) "Rare Disease Diagnostics Summit"
  [2]=>
  string(150) "This Summit will enable partnerships between diagnostic and pharma companies for companion diagnostics, provide a platform for industry to build relat"
  ["short_description"]=>
  string(150) "This Summit will enable partnerships between diagnostic and pharma companies for companion diagnostics, provide a platform for industry to build relat"
  [3]=>
  string(262) "This Summit will enable partnerships between diagnostic and pharma companies for companion diagnostics, provide a platform for industry to build relationships with patient advocacies, and facilitate knowledge-sharing improve early rare genetic disease diagnosis."
  ["description"]=>
  string(262) "This Summit will enable partnerships between diagnostic and pharma companies for companion diagnostics, provide a platform for industry to build relationships with patient advocacies, and facilitate knowledge-sharing improve early rare genetic disease diagnosis."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(63) "https://www.pharmiweb.com/event/rare-disease-diagnostics-summit"
  ["blog_url"]=>
  string(63) "https://www.pharmiweb.com/event/rare-disease-diagnostics-summit"
  [15]=>
  string(19) "2019-04-30 13:38:11"
  ["add_date"]=>
  string(19) "2019-04-30 13:38:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2497"
  ["article_id"]=>
  string(4) "2497"
  [1]=>
  string(103) "Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson's Disease Drug CVN424"
  ["article_title"]=>
  string(103) "Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson's Disease Drug CVN424"
  [2]=>
  string(150) "Boston, MA – April 30, 2019 – Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has succes"
  ["short_description"]=>
  string(150) "Boston, MA – April 30, 2019 – Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has succes"
  [3]=>
  string(243) "Boston, MA – April 30, 2019 – Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has successfully completed its Phase 1 clinical trial of CVN424, the company’s first-in-class,..."
  ["description"]=>
  string(243) "Boston, MA – April 30, 2019 – Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has successfully completed its Phase 1 clinical trial of CVN424, the company’s first-in-class,..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(274) "https://www.drugs.com/clinical_trials/cerevance-achieves-key-endpoints-phase-1-clinical-trial-novel-parkinson-s-cvn424-18145.html?utm_source=ddc&utm_medium=rss&utm_campaign=Cerevance+Achieves+Key+Endpoints+in+Phase+1+Clinical+Trial+of+Novel+Parkinson%27s+Disease+Drug+CVN424"
  ["blog_url"]=>
  string(274) "https://www.drugs.com/clinical_trials/cerevance-achieves-key-endpoints-phase-1-clinical-trial-novel-parkinson-s-cvn424-18145.html?utm_source=ddc&utm_medium=rss&utm_campaign=Cerevance+Achieves+Key+Endpoints+in+Phase+1+Clinical+Trial+of+Novel+Parkinson%27s+Disease+Drug+CVN424"
  [15]=>
  string(19) "2019-04-30 09:05:49"
  ["add_date"]=>
  string(19) "2019-04-30 09:05:49"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:34"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1934"
  ["article_id"]=>
  string(4) "1934"
  [1]=>
  string(121) "Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for Intravenous Contepo (fosfomycin) for injection"
  ["article_title"]=>
  string(121) "Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for Intravenous Contepo (fosfomycin) for injection"
  [2]=>
  string(150) "DUBLIN, Ireland, April 30, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the"
  ["short_description"]=>
  string(150) "DUBLIN, Ireland, April 30, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the"
  [3]=>
  string(251) "DUBLIN, Ireland, April 30, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today that..."
  ["description"]=>
  string(251) "DUBLIN, Ireland, April 30, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today that..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(214) "https://www.drugs.com/nda/contepo_190430.html?utm_source=ddc&utm_medium=rss&utm_campaign=Nabriva+Therapeutics+Receives+Complete+Response+Letter+from+FDA+on+NDA+for+Intravenous+Contepo+%28fosfomycin%29+for+injection"
  ["blog_url"]=>
  string(214) "https://www.drugs.com/nda/contepo_190430.html?utm_source=ddc&utm_medium=rss&utm_campaign=Nabriva+Therapeutics+Receives+Complete+Response+Letter+from+FDA+on+NDA+for+Intravenous+Contepo+%28fosfomycin%29+for+injection"
  [15]=>
  string(19) "2019-04-30 08:04:55"
  ["add_date"]=>
  string(19) "2019-04-30 08:04:55"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1925"
  ["article_id"]=>
  string(4) "1925"
  [1]=>
  string(130) "FDA Approves Kalydeco (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age"
  ["article_title"]=>
  string(130) "FDA Approves Kalydeco (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age"
  [2]=>
  string(150) "BOSTON--(BUSINESS WIRE)--Apr. 30, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced the U.S. Food and Drug Administration (FDA)"
  ["short_description"]=>
  string(150) "BOSTON--(BUSINESS WIRE)--Apr. 30, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced the U.S. Food and Drug Administration (FDA)"
  [3]=>
  string(248) "BOSTON--(BUSINESS WIRE)--Apr. 30, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced the U.S. Food and Drug Administration (FDA) approved Kalydeco (ivacaftor) for use in children with cystic fibrosis (CF) ages six months to..."
  ["description"]=>
  string(248) "BOSTON--(BUSINESS WIRE)--Apr. 30, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced the U.S. Food and Drug Administration (FDA) approved Kalydeco (ivacaftor) for use in children with cystic fibrosis (CF) ages six months to..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-kalydeco-ivacaftor-first-only-cftr-modulator-eligible-infants-cf-early-six-months-age-4964.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Kalydeco+%28ivacaftor%29+as+First+and+Only+CFTR+Modulator+to+Treat+Eligible+Infants+with+CF+as+Early+as+"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-kalydeco-ivacaftor-first-only-cftr-modulator-eligible-infants-cf-early-six-months-age-4964.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Kalydeco+%28ivacaftor%29+as+First+and+Only+CFTR+Modulator+to+Treat+Eligible+Infants+with+CF+as+Early+as+"
  [15]=>
  string(19) "2019-04-30 08:04:53"
  ["add_date"]=>
  string(19) "2019-04-30 08:04:53"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:50"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1908"
  ["article_id"]=>
  string(4) "1908"
  [1]=>
  string(119) "FDA Adds Boxed Warning for Risk of Serious Injuries Caused by Sleepwalking with Certain Prescription Insomnia Medicines"
  ["article_title"]=>
  string(119) "FDA Adds Boxed Warning for Risk of Serious Injuries Caused by Sleepwalking with Certain Prescription Insomnia Medicines"
  [2]=>
  string(150) "Audience: Audience: Consumer, Health Professional, Pharmacy The Food and Drug Administration (FDA) is advising that rare but serious injuries have hap"
  ["short_description"]=>
  string(150) "Audience: Audience: Consumer, Health Professional, Pharmacy The Food and Drug Administration (FDA) is advising that rare but serious injuries have hap"
  [3]=>
  string(248) "Audience: Audience: Consumer, Health Professional, Pharmacy The Food and Drug Administration (FDA) is advising that rare but serious injuries have happened with certain common prescription insomnia medicines because of sleep behaviors, including..."
  ["description"]=>
  string(248) "Audience: Audience: Consumer, Health Professional, Pharmacy The Food and Drug Administration (FDA) is advising that rare but serious injuries have happened with certain common prescription insomnia medicines because of sleep behaviors, including..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(291) "https://www.drugs.com/fda/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-insomnia-medicines-14270.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Adds+Boxed+Warning+for+Risk+of+Serious+Injuries+Caused+by+Sleepwalking+with+Certain+Prescription+Insomnia+Medicines"
  ["blog_url"]=>
  string(291) "https://www.drugs.com/fda/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-insomnia-medicines-14270.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Adds+Boxed+Warning+for+Risk+of+Serious+Injuries+Caused+by+Sleepwalking+with+Certain+Prescription+Insomnia+Medicines"
  [15]=>
  string(19) "2019-04-30 08:00:00"
  ["add_date"]=>
  string(19) "2019-04-30 08:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:50"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2480"
  ["article_id"]=>
  string(4) "2480"
  [1]=>
  string(81) "U.S. FDA Accepts New Drug Application and Grants Priority Review for Darolutamide"
  ["article_title"]=>
  string(81) "U.S. FDA Accepts New Drug Application and Grants Priority Review for Darolutamide"
  [2]=>
  string(150) "WHIPPANY, N.J., April 29, 2019 /PRNewswire/ -- Bayer today announced the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application"
  ["short_description"]=>
  string(150) "WHIPPANY, N.J., April 29, 2019 /PRNewswire/ -- Bayer today announced the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application"
  [3]=>
  string(239) "WHIPPANY, N.J., April 29, 2019 /PRNewswire/ -- Bayer today announced the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review to darolutamide for the treatment of non-metastatic..."
  ["description"]=>
  string(239) "WHIPPANY, N.J., April 29, 2019 /PRNewswire/ -- Bayer today announced the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review to darolutamide for the treatment of non-metastatic..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(175) "https://www.drugs.com/nda/darolutamide_190429.html?utm_source=ddc&utm_medium=rss&utm_campaign=U.S.+FDA+Accepts+New+Drug+Application+and+Grants+Priority+Review+for+Darolutamide"
  ["blog_url"]=>
  string(175) "https://www.drugs.com/nda/darolutamide_190429.html?utm_source=ddc&utm_medium=rss&utm_campaign=U.S.+FDA+Accepts+New+Drug+Application+and+Grants+Priority+Review+for+Darolutamide"
  [15]=>
  string(19) "2019-04-30 07:04:56"
  ["add_date"]=>
  string(19) "2019-04-30 07:04:56"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:27"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2481"
  ["article_id"]=>
  string(4) "2481"
  [1]=>
  string(169) "Janssen Announces Submission of New Drug Application to U.S. FDA For the First Monthly, Injectable, Two-Drug Regimen of Rilpivirine and Cabotegravir for Treatment of HIV"
  ["article_title"]=>
  string(169) "Janssen Announces Submission of New Drug Application to U.S. FDA For the First Monthly, Injectable, Two-Drug Regimen of Rilpivirine and Cabotegravir for Treatment of HIV"
  [2]=>
  string(150) "Cork,Ireland, April 29, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that a New Drug Application (NDA) to"
  ["short_description"]=>
  string(150) "Cork,Ireland, April 29, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that a New Drug Application (NDA) to"
  [3]=>
  string(243) "Cork,Ireland, April 29, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) has been submitted by ViiV Healthcare for the..."
  ["description"]=>
  string(243) "Cork,Ireland, April 29, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) has been submitted by ViiV Healthcare for the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(279) "https://www.drugs.com/nda/cabotegravir_rilpivirine_190429.html?utm_source=ddc&utm_medium=rss&utm_campaign=Janssen+Announces+Submission+of+New+Drug+Application+to+U.S.+FDA+For+the+First+Monthly%2C+Injectable%2C+Two-Drug+Regimen+of+Rilpivirine+and+Cabotegravir+for+Treatment+of+HIV"
  ["blog_url"]=>
  string(279) "https://www.drugs.com/nda/cabotegravir_rilpivirine_190429.html?utm_source=ddc&utm_medium=rss&utm_campaign=Janssen+Announces+Submission+of+New+Drug+Application+to+U.S.+FDA+For+the+First+Monthly%2C+Injectable%2C+Two-Drug+Regimen+of+Rilpivirine+and+Cabotegravir+for+Treatment+of+HIV"
  [15]=>
  string(19) "2019-04-30 06:04:11"
  ["add_date"]=>
  string(19) "2019-04-30 06:04:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:27"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2206"
  ["article_id"]=>
  string(4) "2206"
  [1]=>
  string(71) "PopsiCube opens Russian affiliate to tap into international client base"
  ["article_title"]=>
  string(71) "PopsiCube opens Russian affiliate to tap into international client base"
  [2]=>
  string(137) "CRO PopsiCube opens strategic Russian affiliate to further its international expansion of clinical trial management and digital services."
  ["short_description"]=>
  string(137) "CRO PopsiCube opens strategic Russian affiliate to further its international expansion of clinical trial management and digital services."
  [3]=>
  string(137) "CRO PopsiCube opens strategic Russian affiliate to further its international expansion of clinical trial management and digital services."
  ["description"]=>
  string(137) "CRO PopsiCube opens strategic Russian affiliate to further its international expansion of clinical trial management and digital services."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(177) "https://www.outsourcing-pharma.com/Article/2019/04/29/PopsiCube-opens-Russian-affiliate-to-tap-into-international-client-base?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(177) "https://www.outsourcing-pharma.com/Article/2019/04/29/PopsiCube-opens-Russian-affiliate-to-tap-into-international-client-base?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-04-30 00:40:00"
  ["add_date"]=>
  string(19) "2019-04-30 00:40:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:44"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:44"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2207"
  ["article_id"]=>
  string(4) "2207"
  [1]=>
  string(46) "Almac launches site storage temperature module"
  ["article_title"]=>
  string(46) "Almac launches site storage temperature module"
  [2]=>
  string(142) "TempEZ is a web-based temperature data management software providing a single secure database to collect temperature data from clinical sites."
  ["short_description"]=>
  string(142) "TempEZ is a web-based temperature data management software providing a single secure database to collect temperature data from clinical sites."
  [3]=>
  string(142) "TempEZ is a web-based temperature data management software providing a single secure database to collect temperature data from clinical sites."
  ["description"]=>
  string(142) "TempEZ is a web-based temperature data management software providing a single secure database to collect temperature data from clinical sites."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(152) "https://www.outsourcing-pharma.com/Article/2019/04/29/Almac-launches-site-storage-temperature-module?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(152) "https://www.outsourcing-pharma.com/Article/2019/04/29/Almac-launches-site-storage-temperature-module?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-04-30 00:26:00"
  ["add_date"]=>
  string(19) "2019-04-30 00:26:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:44"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:44"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1965"
  ["article_id"]=>
  string(4) "1965"
  [1]=>
  string(90) "All opioid medicines to contain clear warnings about addiction, health secretary announces"
  ["article_title"]=>
  string(90) "All opioid medicines to contain clear warnings about addiction, health secretary announces"
  [2]=>
  string(150) "All opioid medicines will need to carry prominent warnings about the risk of addiction, health and social care secretary, Matt Hancock, has announced."
  ["short_description"]=>
  string(150) "All opioid medicines will need to carry prominent warnings about the risk of addiction, health and social care secretary, Matt Hancock, has announced."
  [3]=>
  string(150) "All opioid medicines will need to carry prominent warnings about the risk of addiction, health and social care secretary, Matt Hancock, has announced."
  ["description"]=>
  string(150) "All opioid medicines will need to carry prominent warnings about the risk of addiction, health and social care secretary, Matt Hancock, has announced."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(168) "https://www.pharmaceutical-journal.com/news-and-analysis/news/all-opioid-medicines-to-contain-clear-warnings-about-addiction-health-secretary-announces/20206486.article"
  ["blog_url"]=>
  string(168) "https://www.pharmaceutical-journal.com/news-and-analysis/news/all-opioid-medicines-to-contain-clear-warnings-about-addiction-health-secretary-announces/20206486.article"
  [15]=>
  string(19) "2019-04-30 00:16:00"
  ["add_date"]=>
  string(19) "2019-04-30 00:16:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:53"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2208"
  ["article_id"]=>
  string(4) "2208"
  [1]=>
  string(49) "Scaling down: Clinical research shifts its focus "
  ["article_title"]=>
  string(49) "Scaling down: Clinical research shifts its focus "
  [2]=>
  string(152) "Smaller companyâs last year led in new drug approvals, nearly half of which were for the treatment of rare diseases, as the industry shifts away from"
  ["short_description"]=>
  string(152) "Smaller companyâs last year led in new drug approvals, nearly half of which were for the treatment of rare diseases, as the industry shifts away from"
  [3]=>
  string(207) "Smaller companyâs last year led in new drug approvals, nearly half of which were for the treatment of rare diseases, as the industry shifts away from the need to scale infrastructure, says Tufts director."
  ["description"]=>
  string(207) "Smaller companyâs last year led in new drug approvals, nearly half of which were for the treatment of rare diseases, as the industry shifts away from the need to scale infrastructure, says Tufts director."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(153) "https://www.outsourcing-pharma.com/Article/2019/04/29/Scaling-down-Clinical-research-shifts-its-focus?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(153) "https://www.outsourcing-pharma.com/Article/2019/04/29/Scaling-down-Clinical-research-shifts-its-focus?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-04-30 00:07:00"
  ["add_date"]=>
  string(19) "2019-04-30 00:07:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:44"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:44"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}